AIKI Stock , The shares of AIkido Pharma Inc. aiki declined 11.3 percent to lead all premarket decliners on Tuesday, following the biotech company’s 1 for 17 reverse stock split was in effective. The shares had fallen 7.8 percent to a record low adjusted for splits of closing at $4.65 (pre-split 27 cents) in the wake of the reverse split announcement was made public late Friday. The company stated that it anticipates that the reverse split will lift the price enough that it can bring the stock in line with the listing requirements in the Capital Market of Nasdaq. The latest reverse split is the 5th reverse split over the past 11 years, that increased the price by a multiplier of 274,550. The stock is down 53.4 percent in the year until Monday, while the Nasdaq Composite COMP +1.48 percent has dropped 22.9 percent.
Forward-Looking Statements
Certain statements contained in this press release are “forward-looking statements” within the definition of the Federal Securities Laws. Certain words, such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar words, or statements about the company’s intentions, beliefs or expectations that are not yet realized, constitute forward-looking information. Although the Company believes that forward-looking statements to be reasonable however, no undue reliance should be placed on such forward-looking statements that are based on information that was available to us as of the date of this announcement. These statements are based on assumptions and estimates that are current and are subject to uncertainties and risks, including without limitation , those described within the filings of the company to the SEC and, in particular, risks and uncertainties that relate to the business of the Company in those filings. Therefore, the actual results may differ significantly from those stated. The Company does not undertake to amend or update statements regardless of any new information, future events , or any other reason, except as permitted by law.
AIkido Pharma Returns vs. S&P
| 1 YEAR | 5 YEAR | 5 YEAR ANNUALIZED | SINCE IPO | |
|---|---|---|---|---|
| AIKI | -46.60% | -95.73% | -46.78% | -100% |
| S&P | -9.18% | +56.15% | +9.31% | +4,318% |
Assets
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Net Cash | $34.50M | +480.0% |
| Accounts Receivable | – | – |
| Inventory | 0 | – |
Liabilities
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Long Term Debt | $0.70M | – |
| Short Term Debt | $0.04M | – |
Ratios
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Return On Assets | -17.6% | +135.2% |
| Return On Invested Capital | -30.9% | -42.6% |
Cash Flow
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Free Cash Flow | -$2.88M | +51.6% |
| Operating Free Cash Flow | -$2.88M | +51.6% |
Valuation
QUARTERLYANNUAL
| Q4 2021 | Q1 2022 | Q2 2022 | Q3 2022 | YOY CHANGE | |
|---|---|---|---|---|---|
| Price to Earnings | – | – | – | – | – |
| Price to Book | 0.59 | 0.47 | 0.33 | 0.39 | -53.3% |
| Price to Sales | – | – | – | – | – |
| Price to Tangible Book Value | 8.81 | 6.75 | 0.33 | 0.39 | -96.8% |
| Price to Free Cash Flow TTM | – | – | – | – | – |
| Enterprise Value to EBITDA | 10.30 | 6.09 | 7.70 | 1.03 | -90.3% |
| Free Cash Flow Yield | – | – | – | – | – |
| Return on Equity | -10.9% | -6.1% | -11.0% | -18.0% | +136.8% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.74M | – |
